Top Feed
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
Addressing the Inequities Facing Minority Patients With IPF
Exploring the potential of the latest treatment for pulmonary fibrosis
Targeting ‘overlooked’ gene could lead to new treatments for IPF: Study
United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales
Positive Preclinical Data for IPF Drug
Why PDE4B matters in the search for better IPF and PPF therapies
Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State
The p300/CBP inhibitors suppressed fibrotic phenotypes in both in vitro human and in vivo mouse models of pulmonary fibrosis, demonstrating the effectiveness of...
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
AK3280 is an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated...
Addressing the Inequities Facing Minority Patients With IPF
A study that evaluated people with IPF waiting for lung transplants found higher death rates among Black and Hispanic patients.
Exploring the potential of the latest treatment for pulmonary fibrosis
After the approval of JASCAYD® in the U.S. to treat patients with idiopathic pulmonary fibrosis (IPF), Boehringer Ingelheim is pursuing new research...
Targeting ‘overlooked’ gene could lead to new treatments for IPF: Study
The researchers' analyses zeroed in on two TGF-beta-related genes, ACVRL1 and LTBP1, that appear to play central roles in IPF lung disease. Specifically, data...
United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion.
Positive Preclinical Data for IPF Drug
Expanded Therapeutic Potential: These findings position Thykamine as a promising disease-modifying candidate for pulmonary fibrosis and other fibro-inflammatory...
Why PDE4B matters in the search for better IPF and PPF therapies
New pooled data from the Phase III FIBRONEER trials were recently presented at the European Respiratory Society Congress. Nerandomilast is an oral medicine...
Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications
In summary, single-cell profiling of diagnostic-stage IPF ALI cultures revealed epithelial and mesenchymal programmes defined by profibrotic basal cells, primed...
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential
United Therapeutics now has fresh late stage data on Tyvaso sitting in a top tier journal, which represents a clear milestone for any drug developer. With the...
Stats
34552
Rank
13K
Points
0
Videos
16
Articles
0
Reviews
0
Comments